Study of HS-10365 in people with liver problems
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how the body handles the study drug HS-10365 in people with liver problems compared to those with healthy livers. It helps find the right dose and safety information for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your weight must be at least 50 kg (110 lbs) for men, 45 kg (99 lbs) for women.
- Your body mass index (BMI) must be between 18 and 33.
- Your kidneys must work well (creatinine clearance at least 60 mL/min).
- You must agree not to conceive or donate sperm/eggs for 6 months after the study.
- You must not have certain heart issues or take certain medications that could affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a new oral drug (HS-10241) is processed by the body in people with mild to moderate liver disease and in healthy people. It helps find the right dose and safety for future patients with liver problems.
This study looks at how the body handles a new investigational drug (HS-10504) in people with liver problems compared to those with healthy liver function.
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This trial tests an investigational drug, HS-10542, in healthy adults to see how it is processed by the body and to check for side effects. You must be willing to receive two vaccines before the study starts.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.